SELECTED PUBLICATIONS
 |
 |
Brentuximab vedotin (SGN-35) AND CD30-RELATED
The antibody-drug conjugate brentuximab
vedotin (SGN-35) induced multiple objective responses in
patients with relapsed or refractory CD30-positive
lymphomas in a phase 1 weekly dosing study
Fanale, M., et.al.
American Society of Hematology 2009 Annual Meeting (abstract #
2731)
Robust antitumor activity of the antibody-drug conjugate SGN-35 when administered every 3 weeks to patients with relapsed or refractory CD30-positive hematologic malignancies in a phase I study
Younes, A., et.al.
European Hematology Association 2009 Congress (abstract # 503)
Complete remissions with SGN-35 weekly dosing: a phase I dose-escalation study in relapsed/refractory Hodgkin lymphoma or systemic ALCL patients
Bartlett, N.L., et.al.
American Society of Clinical Oncology 2009 Annual Meeting (abstract # 8500)
Antibody-targeted delivery of auristatin with SGN-35 is superior to non-targeted therapy
Alley, S.C., et.al.
American Association for Cancer Research 2009 Annual Meeting (abstract #3234)
Multiple complete responses in a phase I dose-escalation study of the antibody-drug conjugate SGN-35 in
patients with relapsed or refractory CD30-positive lymphomas
Younes, A., et.al.
American Society of Hematology 2008 Annual Meeting (abstract #1006)
Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves
antitumor activity in Hodgkin lymphoma
Oflazoglu, E., et.al.
British Journal of Haematology, 2008, 142(1):69-73
CD30 expression on CD1a+ and CD8+ cells in atopic dermatitis and correlation with disease severity
Oflazoglu, E., et.al.
European Journal of Dermatology, 2008, 18(1):41-9
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
Sutherland, M.S.K., et.al.
Journal of Biological Chemistry, 2006, 281(15):10540-7
In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate
Sanderson, R.J., et.al.
Clinical Cancer Research 2005, 11(2 Pt 1):843-52
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
Francisco, J.A., et.al.
Blood, 2003, 102(4):1458-65
Antibody-Drug Conjugate (ADC) Technology
Contribution of linker stability to the activities of anticancer immunoconjugates
Alley, S.C.,et.al.
Bioconjugate Chemistry, 2008, 19(3):759-65
Novel peptide linkers for highly potent antibody-auristatin conjugate
Doronina, S.O., et.al.
Bioconjugate Chemistry, 2008, 19(10):1960-3
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker
technology on efficacy and toxicity
Doronina, S.O., et.al.
Bioconjugate Chemistry, 2006, 17(1):114-24
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides
Sun, M.M.C., et.al.
Bioconjugate Chemistry, 2005, 16(5):1282-90
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A.M., Senter, P.D.
Nature Biotechnology, 2005, 23(9):1137-46
Effects of drug loading on the antitumor activity of a monoclonal antibody-drug conjugate
Hamblett, K.J., et.al.
Clinical Cancer Research, 2004, 10(20):7063-70
Secondary mAb-vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway
Klussman, K., et.al.
Bioconjugate Chemistry, 2004, 15(4):765-73
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S.O., et.al.
Nature Biotechnology, 2003, 21(7):778-84
Dacetuzumab (SGN-40) and CD40-related
A phase 1b clinical trial of dacetuzumab in
combination with rituximab and gemcitabine: multiple
responses observed in patients with relapsed diffuse
large B-cell lymphoma
Forero-Torres, A., et.al.
American Society of Hematology 2009 Annual Meeting (abstract #
586)
Dacetuzumab (SGN-40), lenalidomide, and
weekly dexamethasone in relapsed or refractory multiple
myeloma: multiple responses observed in a phase 1b study
Agura, E., et.al.
American Society of Hematology 2009 Annual Meeting (abstract #
2870)
Phase I study of the humanized anti-CD40
monoclonal antibody dacetuzumab in refractory or
recurrent non-Hodgkin's lymphoma
Advani, R., et.al.
Journal of Clinical Oncology, 2009, 27(26):4371-7
Dacetuzumab (SGN-40), a humanized anti-CD40 monoclonal antibody, has chemosensitization activity and
improves gemcitabine efficacy in NHL xenograft models
Lewis, T.S., et.al.
American Association for Cancer Research 2009 Annual Meeting (abstract #3243)
A gene signature predicts sensitivity to the partial CD40 agonist, dacetuzumab (SGN-40), in patients with
diffuse large B-cell lymphoma
Burington, B., et.al.
American Association for Cancer Research 2009 Annual Meeting (abstract #LB-138)
Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody
SGN-40
Oflazoglu, E., et.al.
British Journal of Cancer, 2009, 100(1):113-7
A phase 2 clinical trial of SGN-40 (dacetuzumab) monotherapy in relapsed diffuse large B-cell lymphoma
Advani, R., et.al.
American Society of Hematology 2008 Annual Meeting (abstract #1000)
Preclinical analysis of the combined activity of SGN-40 (dacetuzumab), anti-CD40 monoclonal antibody, with
rituximab in non-Hodgkin lymphoma
Lewis, T.S., et.al.
American Society of Hematology 2008 Annual Meeting (abstract # 1583)
SGN-40 shows evidence of activity in patients with relapsed non-Hodgkin's lymphoma: final results of a
phase 1 dose-escalation study
Advani, R., et.al.
International Conference on Malignant Lymphoma, 2008
The humanized anti-CD40 monoclonal antibody, SGN-40, potentiates chemotherapy regimens in NHL
xenograft models via proapoptotic signaling
Lewis, T.S., et.al.
American Society of Hematology 2007 Annual Meeting (abstract #2342)
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40
Law, C.L., et.al.
Cancer Research; 2005, 65(18):8331-8
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in
human multiple myeloma: clinical implications
Tai, Y.T., et.al.
Cancer Research, 2005, 65(24):11712-20
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple
myeloma cells: clinical implications
Tai, Y.T., et.al.
Cancer Research, 2004, 64(8):2846-52
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells
Hayashi, T., et.al.
British Journal of Haematology, 2003, 121(4):592-6
Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax
Szocinski, J.L., et.al.
Blood, 2002, 100(1):217-23
Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14
Francisco, J.A., et.al.
Cancer Research, 2000, 60(12):3225-31
Lintuzumab (SGN-33) AND CD33-RELATED
Complete remissions observed in acute myeloid
leukemia following prolonged exposure to lintuzumab: a
phase 1 trial
Raza, A., et.al.
Leukemia & Lymphoma, 2009, 50:8, 1336-1344
Anti-leukemic activity of lintuzumab (SGN-33)
in preclinical models of acute myeloid leukemia
Sutherland, M.S.K., et.al.
mAbs, 2009, 1:5, 481-490
Prolonged exposure to lintuzumab monotherapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) - results of a phase I trial
Raza, A., et.al.
European Hematology Association 2009 Congress (abstract # 983)
SGN-33, lintuzumab, demonstrates anti-leukemic activity in MDR-positive preclinical models of AML
Sutherland, M.S.K., et.al.
American Association for Cancer Research 2008 Annual Meeting (abstract #1513)
Complete remissions observed in acute myeloid leukemia following prolonged exposure to SGN-33
(lintuzumab), a humanized monoclonal antibody targeting CD33
Raza, A., et.al.
American Society of Hematology 2007 Annual Meeting (abstract #159)
SGN-33 (lintuzumab) demonstrates anti-leukemic activity in preclinical models of AML
Sutherland, M.S.K., et.al.
American Society of Hematology 2007 Annual Meeting (abstract #919)
SGN-33 (lintuzumab) a humanized anti-CD33 antibody, modulates the activity of CD30-positive tumor-
associated macrophages
Sutherland, M.S.K., et.al.
American Association for Cancer Research 2007 Annual Meeting (abstract #4111)
SGN-70
Blocking of CD27/CD70 pathway by anti-CD70
antibody ameliorates joint disease in murine
collagen-induced arthritis
Oflazoglu, E., et.al.
Journal of Immunology, 2009, 183: 3770-3777
Targeting CD70 for the treatment of autoimmune disorders
McEarchern, J.A., et.al.
American College of Rheumatology, 2008 Annual Scientific Meeting
Immune modulation mediated by the humanized anti-CD70 monoclonal antibody SGN-70
Klussman, K., et.al.
American Association of Immunologists / Experimental Biology 2008 Annual Meeting (abstract #LB-457)
Preclinical characterization of SGN-70, a humanized antibody directed against CD70
McEarchern, J.A., et.al.
Clinical Cancer Research, 2008, 14(23):7763-72
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor
activities
McEarchern, J.A., et.al.
Blood, 2007, 109(3):1185-92
SGN-75 AND CD70-RELATED
CD70 expression in multiple types of carcinomas: new targets for auristatin-based anti-CD70 antibody-drug
conjugate SGN-75
Smith, L.M., et.al.
American Association for Cancer Research 2009 Annual Meeting (abstract #4652)
Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor
auristatin via an uncleavable linker
Oflazoglu, E., et.al.
Clinical Cancer Research, 2008, 14(19):6171-80
Biodistribution of a dual labeled anti-CD70 auristatin antibody-drug conjugate in tumor-bearing mice:
experimental and modeled data
Alley, S.C., et.al.
American Association for Cancer Research 2008 Annual Meeting (abstract #4063)
Potent anticarcinoma activity of the anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via
an uncleavable linker
Oflazoglu, E., et.al.
American Association for Cancer Research 2008 Annual Meeting (abstract #4064)
Effects of linker chemistry on tumor targeting by anti-CD70 antibody-drug conjugates
Alley, S.C., et.al.
American Association for Cancer Research 2007 Annual Meeting (abstract #916)
Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates
Law, C.L., et.al.
Cancer Research, 2006, 66(4):2328-37